Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
BioAscent appoints Nick Moore, PhD to steer growth in US
Dr Moore, is an internationally recognized drug discovery specialist with over 35 years’ experience in all aspects of discovery…
Dassault Systèmes holds a virtual conference to highlight the innovations for the Life Sciences…
Speakers from Biocon, IPCA, Skanray, Sahajanand Medical Technologies, Lupin, Agappe Diagnostics, Stryker, Brainsight, COMOFI…
Understanding Virus and Viral Vaccine Development Using Multi Spectral Advanced Nano-Tracking…
By Dr. Namrata Jain, Kanika Thakur, Dr. Jeffrey Bodycomb, Dr. Rajeev Gautam, Dr. John Kiran Anthony
Diabetes drug may lower COVID-19 death risk in women; key immune cells fail to respond to virus
The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments…
US FDA announces first-of-its-kind pilot program to communicate patient reported outcomes from…
Through a new website, Project Patient Voice creates a consistent source of publicly available information describing…
Pig trial of AstraZeneca’s COVID-19 vaccine shows promise with two shots
Research released by Britain’s Pirbright Institute found that giving an initial prime dose followed by a booster dose of the…
Chaos, confusion over customs clearance of China consignments at Chennai, Vizag
However, it came to light that the government has not taken any decision on restricting imports of any essential items from China
Sanofi clinches $2-bn vaccines deal with Translate Bio
The deal strengthens Sanofi’s credentials in a market engaged in a frantic race to find a safe and effective vaccine against the…
Cipla to price remdesivir version for COVID-19 under 5,000 rupees
Cipla, in an e-mailed statement, did not provide details on when the treatment, called Cipremi, will be available
Vaccitech begins Phase 1 clinical study of VTP-300 immunotherapeutic to treat chronic Hepatitis B
Once the VTP-300 prime dose is confirmed, Vaccitech plans to initiate a Phase 1b/2a study, HBV002, in Q3 2020